Pharmacokinetic analysis of carboplatin in postoperative patients with Stage I seminoma

Pharmacokinetic analysis of carboplatin in postoperative patients with Stage I seminoma - Pharmacokinetic analysis of carboplatin in postoperative patients with Stage I seminoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013415

Enrollment

Registered

2014-03-24

Start date

2014-03-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative patients with Stage I seminoma

Interventions

Blood samples (10 points for 24hours) are collected after the administration of carboplatin for pharmacokinetic analysis.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Histologically proven Stage I seminoma patients after sugery 2) Age>=20years 3) Planned to receive carboplatin 4) eGFR>60mL/min 5) ECOG PS:0-1 6)Adequate organ function white-cell count>= 3,000/uL platelet count>= 100,000/uL hemoglobin concentration >= 9.0g/uL 7)Written informed consent 8)Life expectancy more than 3 months

Exclusion criteria

Exclusion criteria: 1) Administration of carboplatin is contraindicated 2) Administration of inulin is contraindicated 3)Judged by investigator to be inappropriate for study participation for serious psychiatric condition 4)Judged by investigator to be inappropriate for study participation for any reason

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics analysis	—

Countries

Japan

Contacts

Public ContactTomoya Shimokata

Nagoya University Hospital Clinical Oncology and Chemotherapy

tshimo@med.nagoya-u.ac.jp052-744-1903

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026